AMGN Today - Aug 08: EMA Backs Repatha Use

カートのアイテムが多すぎます

ご購入は五十タイトルがカートに入っている場合のみです。

カートに追加できませんでした。

しばらく経ってから再度お試しください。

ウィッシュリストに追加できませんでした。

しばらく経ってから再度お試しください。

ほしい物リストの削除に失敗しました。

しばらく経ってから再度お試しください。

ポッドキャストのフォローに失敗しました

ポッドキャストのフォロー解除に失敗しました

AMGN Today - Aug 08: EMA Backs Repatha Use

無料で聴く

ポッドキャストの詳細を見る

Hey there! I’m Joey, your friendly stock enthusiast, breaking down the day’s action. So today we’re talking about Amgen, and it was a green day, up about 1.5%. Not too shabby!

So, what went down? Amgen popped up after some good news from the European Medicines Agency. They gave a thumbs up for broader use of Amgen's heart drug Repatha in high-risk patients. That’s always a boost for a company when regulators back their products. People were feeling it, and the stock got some nice momentum.

Now, here’s where it gets interesting. While the good news was rolling in, there were also some mixed signals. One of Amgen's top execs, Nancy Grygiel, sold off over a million bucks worth of stock. That’s a big move, and it kinda makes people raise an eyebrow. Is she cashing in before something changes? Who knows, but it definitely had some folks hitting the sell button. Also, we saw some changes in holdings with other firms. Teamwork Financial Advisors sold off a chunk, while MRA Advisory Group decided to grab more shares. It’s like a tug-of-war with the stock!

Looking ahead, Amgen’s got some more eyes on it since the Repatha news. Investors will be watching closely to see how that plays out in the next earnings report.

To wrap this up, Amgen had a decent day thanks to solid news about Repatha, but there’s also some caution in the air with those insider sales. Just remember, this is all for your info and fun—no buy or sell tips from me. Catch you later!

まだレビューはありません